Prot #RNLC2131: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Early Decompensated

Project: Research project

StatusFinished
Effective start/end date9/29/1412/31/15

Funding

  • Salix Pharmaceuticals, Inc. (Prot #RNLC2131)